Anavex Life Sciences (AVXL) Amortization - Deferred Charges (2016 - 2018)
Anavex Life Sciences recorded quarterly Amortization - Deferred Charges of $30943.0 in Q2 2018, up 567.31% quarter-over-quarter from $4637.0 in Q3 2016.
Anavex Life Sciences' Amortization - Deferred Charges history runs 2 years deep, the most recent figure standing at $30943.0 for Q2 2018.
- In Q2 2018, Amortization - Deferred Charges changed N/A year-over-year to $30943.0; the TTM figure through Sep 2018 stood at $35588.0 (changed N/A YoY), while the FY2019 annual figure was $151133.0, up 388.42% from the prior year.
- Amortization - Deferred Charges came in at $30943.0 for Q2 2018 at Anavex Life Sciences, up from $4637.0 in the prior quarter.
- In the past five years, Amortization - Deferred Charges ranged from a high of $30943.0 in Q2 2018 to a low of $8.0 in Q2 2016.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortization - Deferred Charges (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 30,943.00 |
| Jun 30, 2018 | 30,943.00 |
| Sep 30, 2016 | 4,637.00 |
| Sep 30, 2016 | 4,637.00 |
| Jun 30, 2016 | 8.00 |
| Jun 30, 2016 | 8.00 |